Doctor's Bio
Dr. Shreyas S. Joshi, MD, is a board-certified urologist who specializes in the diagnosis and treatment of prostate, bladder, kidney, and other urologic cancers. At Grady, he provides personalized cancer care using advanced surgical techniques, including open, laparoscopic, and robotic surgery.
Dr. Joshi earned his medical degree from Indiana University School of Medicine and completed his urology residency at Vanderbilt University Medical Center. He went on to complete advanced fellowship training in urologic oncology at Fox Chase Cancer Center and earned a Master of Public Health from Temple University.
In addition to caring for patients, Dr. Joshi is an Associate Professor of Urology at Emory University School of Medicine. He is committed to helping patients understand their diagnosis and treatment options and providing expert, compassionate care throughout their cancer treatment.
Board Certifications
American Board of Urology
Affiliations
Emory
Education & Training
- Medical School: Indiana University School of Medicine
- Internship: Vanderbilt University
- Residency: Vanderbilt University
Fellowships
Fox Chase Cancer Center
Locations and Directions
Grady Memorial Hospital
Phone: (404) 616-1000
Location:
80 Jesse Hill Jr Drive SE
Atlanta, GA 30303
Publications
- Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
Tyson MD, Nam JK, Joshi SS, Uchio EM, Jung SI, Bivalacqua TJ, Steinberg GD, Shore ND, Burke JM, Kitamura H, Tran B, Li R
The Lancet. Oncology. 2026;27(8):983-993.
PMID: 42508433 - Mental health disorders following nephrectomy for renal cell carcinoma: a national study.
Esen B, Lahiji R, Patil D, Mumford S, Landrum KR, Nabavizadeh R, Hajiha M, Grajales V, Khater N, Joshi SS, Narayan VM, Ogan K, Master VA
BJU international. 2026;
PMID: 42433145 - Understanding the utilization of genetic counseling and testing among patients with prostate cancer.
Morton EA, Lahiji R, Chu E, Luke W, Anyaeche VI, Patil D, Mehta A, Joshi SS, Goodstein TA, Grajales V, Hajiha M
The Canadian journal of urology. 2026;33(3):545-553.
PMID: 42415575 - Sarcopenia is associated with poor survival among patients with non-metastatic renal cell carcinoma and venous tumor thrombus.
Lahiji R, Esen B, Son LL, Pail D, Koltur C, Mumford S, Schmeusser BN, Luke W, Storino Ramacciotti L, Morton EA, Goodstein TA, Braunschweig A, Nabavizadeh R, Narayan VN, Grajales V, Joshi SS, Hajiha M, Khater N, Ogan K, Psutka SP, Master VA
World journal of urology. 2026;
PMID: 42406172 - Evaluating the Diagnostic Performance of Clear Cell Likelihood Score in Predicting Clear Cell Renal Cell Carcinoma Among Patients Younger Than 50 Years.
Abdollahzadeh A, Lahiji R, Harris M, Patil D, Gupta A, Majeed NF, Sekhar A, Palmateer G, Morton EA, Ramacciotti LS, Grajales V, Joshi SS, Narayan VM, Nabavizadeh R, Hajiha M, Pedrosa I, Ogan K, Master VA
JCO oncology practice. 2026;
PMID: 42296450 - Laboratory paraneoplastic syndrome resolution is associated with reduced recurrence and improved survival in non-metastatic renal cell carcinoma.
Lahiji R, Son LL, Mumford S, Kearns EJ, Patil D, Ambadi S, Nguyen JT, Esen B, Luke W, Storino Ramacciotti L, Goodstein T, Morton EA, Braunschweig A, Nabavizadeh R, Narayan VN, Grajales V, Joshi SS, Hajiha M, Ogan K, Master VA
Urologic oncology. 2026;44(6):128-134.
PMID: 41936531 - Case Report: Looks can deceive: acute postoperative progressive renal dysfunction and hyperkalemia without significant hydronephrosis.
Lahiji R, Yildirim A, Luke W, Storino Ramacciotti L, Morton EA, Helman TA, Nguyen J, Grajales V, Joshi SS, Narayan VM, Nabavizadeh B, Hajiha M, Nabavizadeh R, Park PJ, Ogan K, Bilen MA, Master VA
Frontiers in oncology. 2026;
PMID: 41695356 - Reply to Editorial Comment on "Understanding Chronic Opioid Use Risk Associated With Penile Cancer Treatments: A National Analysis".
Lahiji R, Joshi SS
Urology. 2026;
PMID: 41620131 - [F]-Fluciclovine or [Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial.
Jani AB, Dhere VR, Goyal S, Schreibmann E, Patel PR, Hershatter B, Shelton JW, Hanasoge S, Sebastian NT, Patel SA, Halkar R, Cooper S, Fielder B, Abiodun-Ojo OA, Lawal I, Mushtaq A, Master VA, Joshi SS, Kucuk O, Bilen MA, Schuster DM
European urology. 2026;89(4):368-377.
PMID: 41412908 - Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.
Wummer B, Schwartz M, Ciuro J, Ahmed S, Joshi SS, Narayan VM, Carthon BC, Bilen MA, Brown JT
Frontiers in oncology. 2025;
PMID: 41409251
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.